As we step into 2024, the biotechnology industry stands at a pivotal point, driven by rapid advancements in technology and shifting market dynamics. The past few years have been transformative, with groundbreaking innovations reshaping the landscape of healthcare, drug development, and beyond. Experts in the field believe that the biotech industry is poised for recovery in 2024, and one reason for that would be a favorable climate for M&A activity. A PwC report predicts the M&A deal totals could range from $225 billion to $275 billion. M&A will be among the trends that will influence the biotech market in 2024.